Viking Global Investors LP

Viking Global Investors LP discloses dealings in 20 companies, chiefly Urovant Sciences Ltd., APi Group Corp and Amylyx Pharmaceuticals, Inc. We count 165 filings; the first trade dates from 8 February 2015 and the latest from 7 October 2025.

In open-market terms, that means 68 purchases worth €398.3M on one side and 49 sales worth €1.5B on the other. The amount is not disclosed for 14 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2025 to date brings no purchases and 5 sales.

In size, the median ticket on the buying side is €501k. Of 66 purchases, 39 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. After 8 purchases with a full 90-day history, the hit rate stands at 13% and the median 90-day move at -17.1%. These figures describe past trades and do not predict future prices.

The latest filing, published on 9 October 2025, reports an open-market sale of €451k in Inhibrx Biosciences, Inc. The last insider purchase was made public on 21 September 2023, 1,128 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.